Key result
The addition of aliskiren to concomitant antihypertensive drugs significantly improved carotid-femoral pulse wave velocity (from 9.36 to 8.72 m/s, p=0.04) and endothelial function.
Why the study?
Does the addition of aliskiren improve arterial stiffness and endothelial function in patients with uncontrolled primary hypertension?
Observational (n=30)
Open-label
No
Does the addition of aliskiren improve arterial stiffness and endothelial function in patients with uncontrolled primary hypertension?
The addition of aliskiren to standard antihypertensive therapy in patients with uncontrolled hypertension improves aortic stiffness and endothelial function, though it may worsen renal function and increase potassium levels.
Aliskiren add-on was associated with improved stiffness in uncontrolled hypertension; hypothesis-generating and should not change practice pending RCTs.
Arterial stiffness and endothelial dysfunction are important determinants of cardiovascular events in patients with arterial hypertension. There are few data regarding the role of aliskiren on the central hemodynamics and endothelial function in patients with uncontrolled arterial hypertension. The aim of this study was to assess the addition of aliskiren to other antihypertensive drug treatment for arterial stiffness and endothelial function. Thirty uncontrolled hypertensive patients (mean age, 60.4±12.2 years), without any other cardiovascular risk factors, were enrolled. Augmentation index (AIx) and carotid-femoral pulse wave velocity (cfPWV) by applanation tonometry and reactive hyperemia peripheral arterial tonometry (RH PAT) index using peripheral arterious tonometry at baseline and after 6 months of aliskiren titrated to 300 mg once a day was evaluated. The addition of aliskiren had no effect on values of central AIx (33.26±10.74% vs 28.86±10.74%; P=.36) but did significantly improve values of cfPWV (9.36±2.65 m/s vs 8.72±2.48 m/s; P=.04) and RH PAT index (1.64±0.57 vs 1.75±0.45; P=.05). In addition to improving systolic and diastolic blood pressure, the addition of aliskiren to concomitant antihypertensive drugs in uncontrolled hypertensive patients may be effective in improving aortic stiffness and endothelial function. These results encourage further studies to evaluate the use of aliskiren for cardiovascular prevention.
No takes yet. Share an insight, caveat, or question.
Bonadei et al. (2014) conducted an observational in Primary Hypertension (n=30). Aliskiren vs. Baseline was evaluated on Carotid-femoral pulse wave velocity (cfPWV) (p=0.04). The addition of aliskiren to concomitant antihypertensive drugs significantly improved carotid-femoral pulse wave velocity (from 9.36 to 8.72 m/s, p=0.04) and endothelial function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: